Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Latest Information Update: 25 Apr 2026
At a glance
- Drugs TQB 3205 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 20 Apr 2026 Status changed from not yet recruiting to recruiting.
- 28 Mar 2026 New trial record